Track Docket
Download Docs
Export
Judge 
Party 
Law Firm HempmeCBD, In the Matter of
2023047 | Federal Trade Commission
Interested in this case?
Request a Demo Track this case, and find millions of cases like it, let us show you how.
Filed
Dec. 17, 2020
Case Flags
Consumer Protection,
Advertising and Marketing,
and
Health Claims
FTC Matter/File Number
2023047
Case Summary
In December 2020, the FTC announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The Commission took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others. A summary of the proposed orders setting the agency’s respective complaint is provided below.
HempmeCBD. The proposed administrative order prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It also requires them to have competent and reliable scientific evidence when making any other health-related product claims. It requires the respondents to pay the FTC $36,254 and to notify consumers of the Commission’s order.
In December 2020, the FTC announced its first law enforcement crackdown on deceptive claims in the growing market for cannabidiol (CBD) products. The Commission took action against six sellers of CBD-containing products for allegedly making a wide range of scientifically unsupported claims about their ability to treat serious health conditions, including cancer, heart disease, hypertension, Alzheimer’s disease, and others. A summary of the proposed orders setting the agency’s respective complaint is provided below.
HempmeCBD. The proposed administrative order prohibits the respondents from making certain prevention, treatment, or safety claims about dietary supplements, foods, and drugs, unless they have the human clinical testing to substantiate the claims. It also requires them to have competent and reliable scientific evidence when making any other health-related product claims. It requires the respondents to pay the FTC $36,254 and to notify consumers of the Commission’s order.
Case Type
Administrative
Last Updated: 3 years, 3 months ago
| Filing Date | # | Docket Text |
|---|
